This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rudolph, P. Articles by Coindre, J. M. Search for Related Content PubMed PubMed Citation Articles by Rudolph, P. Articles by Coindre, J. M.

American Journal of Pathology, Vol 150, 1997-2007, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Prognostic relevance of a novel proliferation marker, Ki-S11, for soft- tissue sarcoma. A multivariate study

P Rudolph, U Kellner, A Chassevent, F Collin, F Bonichon, R Parwaresch and JM Coindre
Department of Pathology, University of Kiel, Germany.

In 132 soft-tissue sarcomas and 52 benign soft-tissue tumors, cellular proliferation was examined by immunohistochemistry using monoclonal antibodies Ki-S11 (Ki-67 antigen) and Ki-S1 (topoisomerase II alpha) and by flow cytometric analysis of the S-phase fraction (SPF). Malignant tumors were graded histologically according to the Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system. Patient age, sex, tumor location, histological type, and DNA ploidy were considered as additional prognostic variables. Consistent immunoreactivity was seen in approximately 95% of the cases, and determination of SPF was possible in approximately 60% Ki-S11 and Ki-S1 immunolabeling indices correlated in a linear manner. All proliferation parameters yielded significant differences between benign and malignant tumors. Ki-S11 and Ki-S1 immunoreactive scores also co-varied significantly with SPF, mitotic count, and histopathological grade. In univariate analysis, immunohistochemical proliferation indices, histopathological grade, mitotic count, and SPF were predictive of overall survival and the development of metastases. In multivariate analysis, immunolabeling scores of proliferation markers, grade, and SPF emerged as independent predictors of global survival and systemic progression. We conclude that the immunohistochemical assessment of proliferation, being more readily performable and more easily assessable than the equally relevant S phase fraction, may add appreciable information to the current prognostic models for soft- tissue sarcoma.

This article has been cited by other articles:

				T. Takahiro, K. Shinichi, and S. Toshimitsu Expression of Fatty Acid Synthase as a Prognostic Indicator in Soft Tissue Sarcomas Clin. Cancer Res., June 1, 2003; 9(6): 2204 - 2212. [Abstract] [Full Text] [PDF]

				C F Lindboe and S H Torp Comparison of Ki-67 equivalent antibodies J. Clin. Pathol., June 1, 2002; 55(6): 467 - 471. [Abstract] [Full Text] [PDF]

				A. L. Folpe, R. H. Lyles, J. T. Sprouse, E. U. Conrad III, and J. F. Eary (F-18) Fluorodeoxyglucose Positron Emission Tomography as a Predictor of Pathologic Grade and Other Prognostic Variables in Bone and Soft Tissue Sarcoma Clin. Cancer Res., April 1, 2000; 6(4): 1279 - 1287. [Abstract] [Full Text]

				P. Rudolph, C. Schubert, S. Tamm, K. Heidorn, A. Hauschild, I. Michalska, S. Majewski, G. Krupp, S. Jablonska, and R. Parwaresch Telomerase Activity in Melanocytic Lesions : A Potential Marker of Tumor Biology Am. J. Pathol., April 1, 2000; 156(4): 1425 - 1432. [Abstract] [Full Text] [PDF]

				P. Rudolph, P. Alm, H.-J. Heidebrecht, H. Bolte, V. Ratjen, B. Baldetorp, M. Ferno, H. Olsson, and R. Parwaresch Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer J Natl Cancer Inst, February 3, 1999; 91(3): 271 - 278. [Abstract] [Full Text] [PDF]